Primaa Raises €7M To Fuel Growth And Global Expansion

The round was supported by MH Innov’ and Elaia’s partnership fund, SWEN Capital Partners, Super Capital, and members of the Wendel family.

Primaa develops AI tools that help detect cancer biomarkers and streamline diagnostic workflows. Its Cleo Breast tool (CE-IVDR certified) assists pathologists in identifying and quantifying key biomarkers in breast cancer, while Cleo Skin, currently under CE marking, focuses on diagnosing melanoma, squamous cell carcinoma, and basal cell carcinoma.

Read Also - Dott Extends Series B Round To $150M To Boost E-bike Growth

The company’s goal is to make diagnostics faster, more reliable, and less labor-intensive for medical professionals.

As well as saving time and improving accuracy in diagnostics, our tools make life much easier for practitioners. The automatic counting and detection features completely relieve them of certain time-consuming tasks, said Fanny Sockeel, CEO and co-founder of Primaa.

Cleo Breast and Cleo Skin are already used by top medical institutions in France, including Institut Curie, AP-HP, and Saint-Joseph Hospital, and are now expanding to European centres like ZAS Laboratory and Liège University Hospital.

Primaa is also developing new AI tools for cervical cancer (with AP-HP and Medipath) and prostate cancer (with Erasme Hospital in Belgium).

The latest funding will help strengthen sales operations for faster European rollout, improve customer support, and speed up development of predictive AI models for tracking disease progression and relapse risk. It will also back Primaa’s international expansion, including FDA certification efforts in the U.S.

About Primaa

Primaa develops AI-powered software that automates and improves histological and cancer diagnostics. By detecting key biomarkers and enhancing diagnostic accuracy, its solutions help pathologists deliver faster more reliable results while reducing workloads and improving consistency in cancer detection.